https://rx-delta.com/blog/ndc-changes-impact-pharmacy-reimbursement-2025 https://zrvgwegglpprtxinfgup.supabase.co/storage/v1/object/public/images/hero/ndc-changes-impact-pharmacy-reimbursement-2025.webp How NDC Changes Impact Pharmacy Reimbursement in 2025 Discover 10 critical ways NDC changes affect pharmacy reimbursement in 2025. Learn strategies to protect revenue and optimize claims processing. https://rx-delta.com/blog/revenue-strategies-independent-pharmacies-2026 https://zrvgwegglpprtxinfgup.supabase.co/storage/v1/object/public/images/hero/revenue-strategies-independent-pharmacies-2026.webp Top Revenue Strategies for Independent Pharmacies in 2026 Discover proven revenue strategies for independent pharmacies including clinical services, specialty dispensing, and technology optimization to boost profitability in 2026. https://rx-delta.com/blog/dir-fees-explained-pharmacists-2025 https://zrvgwegglpprtxinfgup.supabase.co/storage/v1/object/public/images/hero/dir-fees-explained-pharmacists-2025.webp DIR Fees Explained: What Pharmacists Need to Know in 2025 Complete guide to DIR fees in 2025. Learn how these pharmacy reimbursement clawbacks impact your bottom line and strategies to protect profitability. https://rx-delta.com/blog/pharmacy-profit-margin-benchmarks-guide https://zrvgwegglpprtxinfgup.supabase.co/storage/v1/object/public/images/hero/pharmacy-profit-margin-benchmarks-guide.webp Pharmacy Profit Margins by Category: Benchmarks and Improvement Guide Explore pharmacy profit margin benchmarks across prescription types, OTC products, and clinical services. Learn data-driven strategies to improve margins in 2025. https://rx-delta.com/blog/ndc-swap-hidden-revenue-leaks-pharmacy https://zrvgwegglpprtxinfgup.supabase.co/storage/v1/object/public/images/hero/ndc-swap-hidden-revenue-leaks-pharmacy.webp What Is an NDC Swap? 10 Hidden Revenue Leaks in Pharmacy NDC swaps cost pharmacies thousands monthly. Discover 10 hidden revenue leaks from NDC code mismatches and wholesaler substitutions. https://rx-delta.com/blog/pharmacy-claims-reconciliation-tools https://zrvgwegglpprtxinfgup.supabase.co/storage/v1/object/public/images/hero/pharmacy-claims-reconciliation-tools.webp Pharmacy Claims Reconciliation Tools: 6 Best for 2026 Compare the top 6 pharmacy claims reconciliation platforms for 2026. Expert analysis of features, pricing, and integration capabilities. https://rx-delta.com/blog/pharmacy-workflow-automation-guide https://zrvgwegglpprtxinfgup.supabase.co/storage/v1/object/public/images/hero/pharmacy-workflow-automation-guide.webp Pharmacy Workflow Automation: How to Reduce Manual Tasks by 60% Learn how pharmacy workflow automation tools can eliminate repetitive tasks, reduce errors, and free pharmacist time for clinical services. Practical guide with ROI data. https://rx-delta.com/blog/strategies-negotiating-better-pbm-reimbursement-terms https://zrvgwegglpprtxinfgup.supabase.co/storage/v1/object/public/images/hero/strategies-negotiating-better-pbm-reimbursement-terms.webp Strategies for Negotiating Better PBM Reimbursement Terms Master PBM contract negotiations with 10 proven strategies. Learn data-driven approaches to secure better reimbursement rates and terms. https://rx-delta.com/blog/best-pharmacy-management-software-2026 https://zrvgwegglpprtxinfgup.supabase.co/storage/v1/object/public/images/hero/best-pharmacy-management-software-2026.webp Best Pharmacy Management Software Compared (2026) Compare the top pharmacy management software platforms for 2026 including PioneerRx, Liberty, QS/1, and more. Find the right PMS for your pharmacy operations. https://rx-delta.com/blog/pharmacy-revenue-loss-billing-errors https://zrvgwegglpprtxinfgup.supabase.co/storage/v1/object/public/images/hero/pharmacy-revenue-loss-billing-errors.webp How Much Revenue Is Your Pharmacy Losing to Billing Errors? Discover the 10 most costly pharmacy billing errors causing revenue loss. Learn how PBM underpayments and rejected claims drain profits. https://rx-delta.com/blog/340b-drug-pricing-program-eligibility-guide https://zrvgwegglpprtxinfgup.supabase.co/storage/v1/object/public/images/hero/340b-drug-pricing-program-eligibility-guide.webp 340B Drug Pricing Program Eligibility: Complete Guide for Pharmacies Learn which pharmacies and covered entities qualify for the 340B Drug Pricing Program, how to apply, and strategies to maximize savings while staying compliant. https://rx-delta.com/blog/generic-drug-substitution-tracking-pharmacists-guide https://zrvgwegglpprtxinfgup.supabase.co/storage/v1/object/public/images/hero/generic-drug-substitution-tracking-pharmacists-guide.webp Generic Drug Substitution Tracking: A Pharmacist's Guide Master generic drug substitution tracking with our comprehensive guide. Learn 10 essential systems and strategies to optimize pharmacy operations. https://rx-delta.com/newsletter/2026-01-29-cms-340b-oversight-rules-2026 https://zrvgwegglpprtxinfgup.supabase.co/storage/v1/object/public/images/hero/2026-01-29-cms-340b-oversight-rules-2026.webp New CMS Rules Reshape 340B Program Oversight for 2026 PLUS: Hospital outpatient drug spending surges, insulin pricing update, and pharmacy quality measure changes https://rx-delta.com/newsletter/2026-01-08-cvs-restructuring-retail-pharmacy https://zrvgwegglpprtxinfgup.supabase.co/storage/v1/object/public/images/hero/2026-01-08-cvs-restructuring-retail-pharmacy.webp CVS Health Restructuring Plan Shakes Up Retail Pharmacy Landscape PLUS: Walgreens explores going private, generic drug pricing trends, and pharmacy technician shortage deepens https://rx-delta.com/newsletter/2025-12-11-medicare-part-d-2026-changes https://zrvgwegglpprtxinfgup.supabase.co/storage/v1/object/public/images/hero/2025-12-11-medicare-part-d-2026-changes.webp Medicare Part D Changes Bring Relief for Seniors' Drug Costs in 2026 PLUS: Pharmacy deserts expand, biosimilar Humira gains market share, and new antibiotic wins FDA approval https://rx-delta.com/newsletter/2026-02-05-biosimilar-adoption-surges https://zrvgwegglpprtxinfgup.supabase.co/storage/v1/object/public/images/hero/2026-02-05-biosimilar-adoption-surges.webp Biosimilar Adoption Surges as Patents Expire on Major Biologics PLUS: New adalimumab biosimilar enters market, oncology biosimilar pipeline expands, and payer formulary shifts accelerate https://rx-delta.com/newsletter/2026-02-10-digital-health-transforms-pharmacy https://zrvgwegglpprtxinfgup.supabase.co/storage/v1/object/public/images/hero/2026-02-10-digital-health-transforms-pharmacy.webp Digital Health Integration Transforms Modern Pharmacy Practice PLUS: AI clinical tools gain traction, remote patient monitoring expands, and pharmacy apps reshape patient engagement https://rx-delta.com/newsletter/2025-12-18-pharmacy-year-in-review-2025 https://zrvgwegglpprtxinfgup.supabase.co/storage/v1/object/public/images/hero/2025-12-18-pharmacy-year-in-review-2025.webp Pharmacy Industry Year in Review: The Biggest Stories of 2025 PLUS: Top drug launches, regulatory milestones, and what shaped pharmacy practice this year https://rx-delta.com/newsletter/2026-02-12-harm-reduction-programs-gain-ada-legal-protections https://zrvgwegglpprtxinfgup.supabase.co/storage/v1/object/public/images/hero/2026-02-12-harm-reduction-programs-gain-ada-legal-protections.webp Harm reduction programs gain ADA legal protections PLUS: AstraZeneca targets 25+ blockbusters by 2030, fentanyl smoking linked to fewer overdoses, Hims faces regulatory scrutiny https://rx-delta.com/newsletter/2026-01-22-independent-pharmacies-fight-pbm https://zrvgwegglpprtxinfgup.supabase.co/storage/v1/object/public/images/hero/2026-01-22-independent-pharmacies-fight-pbm.webp Independent Pharmacies Fight Back Against PBM Practices PLUS: FTC releases damning PBM report, state attorney general actions, and pharmacy coalition gains momentum https://rx-delta.com/newsletter/2026-02-20-fda-reverses-course-on-moderna-s-flu-vaccine-review https://zrvgwegglpprtxinfgup.supabase.co/storage/v1/object/public/images/hero/2026-02-20-fda-reverses-course-on-moderna-s-flu-vaccine-review.webp FDA reverses course on Moderna's flu vaccine review PLUS: New standard for drug approvals, psilocybin heads to FDA, and Grail's cancer test setback https://rx-delta.com/newsletter/2026-01-15-fda-accelerates-generic-approvals https://zrvgwegglpprtxinfgup.supabase.co/storage/v1/object/public/images/hero/2026-01-15-fda-accelerates-generic-approvals.webp FDA Accelerates Generic Drug Approvals in Push for Lower Prices PLUS: New compounding regulations proposed, telepharmacy expansion, and specialty drug pipeline update https://rx-delta.com/newsletter/2026-01-02-pharmacy-trends-predictions-2026 https://zrvgwegglpprtxinfgup.supabase.co/storage/v1/object/public/images/hero/2026-01-02-pharmacy-trends-predictions-2026.webp What's Ahead for Pharmacy in 2026: Trends and Predictions PLUS: New year drug launches, reimbursement outlook, and technology trends to watch https://rx-delta.com/newsletter/2025-12-04-eli-lilly-weight-loss-expansion https://zrvgwegglpprtxinfgup.supabase.co/storage/v1/object/public/images/hero/2025-12-04-eli-lilly-weight-loss-expansion.webp Eli Lilly's Weight-Loss Drug Expansion Signals New Era in Obesity Treatment PLUS: Novo Nordisk supply chain update, pharmacy benefit reform advances, and CVS earnings surprise https://rx-delta.com/newsletter/2026-03-10-vinay-prasad-exits-fda-as-biotech-stocks-rally https://zrvgwegglpprtxinfgup.supabase.co/storage/v1/object/public/images/hero/2026-03-10-vinay-prasad-exits-fda-as-biotech-stocks-rally.webp Vinay Prasad Exits FDA as Biotech Stocks Rally PLUS: BioNTech founders launch new mRNA venture, Novo strikes Hims deal, and Vertex kidney drug succeeds in trial https://rx-delta.com/newsletter/2026-03-13-fda-launches-unified-safety-surveillance-system https://zrvgwegglpprtxinfgup.supabase.co/storage/v1/object/public/images/hero/2026-03-13-fda-launches-unified-safety-surveillance-system.webp FDA Launches Unified Safety Surveillance System PLUS: Lilly warns of impurities in GLP-1 knockoffs, commits $3B to China manufacturing, and MedPAC calls out Medicare Advantage overpayments https://rx-delta.com/newsletter/2026-02-22-doj-sues-ohiohealth-over-anticompetitive-contracts https://zrvgwegglpprtxinfgup.supabase.co/storage/v1/object/public/images/hero/2026-02-22-doj-sues-ohiohealth-over-anticompetitive-contracts.webp DOJ sues OhioHealth over anticompetitive contracts PLUS: Grail's cancer test misses study goal, Supreme Court strikes down tariffs, and Vertex's CRISPR therapy rebounds https://rx-delta.com/newsletter/2026-02-24-novo-s-obesity-drug-fails-against-lilly-s-zepbound https://zrvgwegglpprtxinfgup.supabase.co/storage/v1/object/public/images/hero/2026-02-24-novo-s-obesity-drug-fails-against-lilly-s-zepbound.webp Novo's Obesity Drug Fails Against Lilly's Zepbound PLUS: Gilead's $7.8B Arcellx buy, FDA's gene therapy roadmap, and Merck's oncology split https://rx-delta.com/newsletter/2026-02-27-lilly-s-glp-1-pill-beats-novo-s-rybelsus-in-phase-3 https://zrvgwegglpprtxinfgup.supabase.co/storage/v1/object/public/images/hero/2026-02-27-lilly-s-glp-1-pill-beats-novo-s-rybelsus-in-phase-3.webp Lilly's GLP-1 pill beats Novo's Rybelsus in Phase 3 PLUS: FDA faces Senate scrutiny on rare disease reviews, Sarepta CEO announces retirement, and Generate raises $400M in IPO https://rx-delta.com/newsletter/2026-03-03-cms-halts-elevance-medicare-advantage-enrollment https://zrvgwegglpprtxinfgup.supabase.co/storage/v1/object/public/images/hero/2026-03-03-cms-halts-elevance-medicare-advantage-enrollment.webp CMS Halts Elevance Medicare Advantage Enrollment PLUS: FDA approves Ascendis dwarfism drug, UniQure gene therapy setback, AI chatbot gets breakthrough status https://rx-delta.com/newsletter/2026-03-06-lilly-bypasses-insurers-with-employer-glp-1-program https://zrvgwegglpprtxinfgup.supabase.co/storage/v1/object/public/images/hero/2026-03-06-lilly-bypasses-insurers-with-employer-glp-1-program.webp Lilly bypasses insurers with employer GLP-1 program PLUS: Moderna settles COVID vaccine patent fight for $2.25B, FDA cracks down on compounded weight loss drugs https://rx-delta.com/newsletter/2026-03-17-judge-blocks-rfk-jr-vaccine-policy-overhaul https://zrvgwegglpprtxinfgup.supabase.co/storage/v1/object/public/images/hero/2026-03-17-judge-blocks-rfk-jr-vaccine-policy-overhaul.webp Judge blocks RFK Jr. vaccine policy overhaul PLUS: Oral GLP-1 pill shows promising weight loss results, GSK expands RSV vaccine, and White House pushes most-favored nation drug pricing https://rx-delta.com/newsletter/2026-03-20-lilly-s-triple-g-obesity-drug-hits-phase-3-milestone https://zrvgwegglpprtxinfgup.supabase.co/storage/v1/object/public/images/hero/2026-03-20-lilly-s-triple-g-obesity-drug-hits-phase-3-milestone.webp Lilly's triple-G obesity drug hits Phase 3 milestone PLUS: Novo's high-dose Wegovy wins FDA approval, J&J's oral psoriasis pill clears regulatory hurdles, and NIH funding crisis deepens https://rx-delta.com/newsletter/2026-03-24-pfizer-s-lyme-vaccine-moves-forward-despite-mixed-data https://zrvgwegglpprtxinfgup.supabase.co/storage/v1/object/public/images/hero/2026-03-24-pfizer-s-lyme-vaccine-moves-forward-despite-mixed-data.webp Pfizer's Lyme vaccine moves forward despite mixed data PLUS: FDA expands Rhythm's obesity drug, Parkinson's med safety updates, and 22,000+ pharma job cuts in 2025 https://rx-delta.com/newsletter/2026-03-27-merck-acquires-terns-for-6-7b-in-oncology-bet https://zrvgwegglpprtxinfgup.supabase.co/storage/v1/object/public/images/hero/2026-03-27-merck-acquires-terns-for-6-7b-in-oncology-bet.webp Merck acquires Terns for $6.7B in oncology bet PLUS: FDA approves rare disease therapies for Hunter syndrome and ovarian cancer, medical schools drop equity requirements